microRNA Replacement Therapy
Publications

PDL1 regulation by p53 via miR-34. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. (2016) J Natl Cancer Inst 108: djv303. Epub 2015 Sep 25.

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. (2015) Oncogene 34: 3547-55. Epub 2014 Sep 1.

Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J, Brown D. (2014). Mol Cancer Ther. 13: 2352-60. Epub 2014 Jul 22.

In-depth analysis shows synergy between erlotinib and miR-34a. Zhao J, Kelnar K, Bader AG (2014). PLOS One, Feb 14, e8910.

miR-34–a microRNA replacement therapy is headed to the clinic. Bader AG (2012). Front Genet 3: article 120.

Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Muller A (2012). Leukemia 26:2421-4.

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011). Nat Med 17: 211-5.

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW. Mol Ther. 2014 May 5 [Epub ahead of print]. doi: 10.1038/mt.2014.79.

In-depth analysis shows synergy between erlotinib and miR-34a. Zhao J, Kelnar K, Bader AG (2014). PLOS One, Feb 14, e8910.

Quantification of therapeutic miRNA mimics in whole blood from non-human primates. Kelnar K, Peltier HJ, Leatherbury N, Stoudemire J, Bader AG (2014) Anal Chem 86: 1534-42.

TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1). Zhao J, Lammers P, Torrance CJ, Bader AG (2013). Mol Ther 21:1678-86.

Distinct microRNA Expression Profiles in Prostate Cancer Stem/Progenitor Cells and Tumor-Suppressive Functions of let-7. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG (2012). Cancer Res 72:3393-404.

Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Muller A (2012). Leukemia 26:2421-4.

Systemic Delivery of Tumor Suppressor microRNA Mimics using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Trang P, Wiggins JF, Daige DL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ (2011). Mol Ther 19:1116-22.

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011). Nat Med 17: 211-5.

Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG (2010). Cancer Res 70: 5923-30.

Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T (2010). Mol Ther 18: 181-7.

Regression of murine lung tumors by the let-7 microRNA. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ (2009). Oncogene 29: 1580-7.

Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA (2008). J Alzheimers Dis 14: 27-41.

The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ (2008). Cell Cycle 7: 759-64.

Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D (2007). Cancer Res 67: 10782-8.

The let-7 microRNA represses cell proliferation pathways in human cells. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ (2007). Cancer Res 67: 7713-22.

RAS is regulated by the let-7 microRNA family. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005). Cell 120: 635-47.
miR-34–a microRNA replacement therapy is headed to the clinic. Bader AG (2012). Front Genet 3: article 120.

Developing therapeutic microRNAs for cancer. Bader AG, Brown D, Stoudemire J, Lammers P (2011). Gene Ther 18:1121-6.

The Therapeutic Potential of microRNAs. Bader AG, Lammers P (2011). Innovations in Pharmaceutical Technology March Issue: 52-55.

The promise of microRNA replacement therapy. Bader AG, Brown D, Winkler M (2010). Cancer Res 70: 7027-30.

Applying small RNA molecules to the directed treatment of human diseases: realizing the potential. Pappas TC, Bader AG, Andruss BF, Brown D, Ford LP (2008). Expert Opin Ther Targets 12: 115-27.
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.